Alsactide
Also known as: Ac-ACTH(1-17)-NH2, ACTH 1-17 synthetic analogue, ACTH(1-24), Alsactide, Alsactide acetate, Cosyntropin, Synacthen, Synchrodyn, Tetracosactide
Source Alsactide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Alsactide (tetracosactide, ACTH 1‑24) is a synthetic peptide used diagnostically to assess adrenal function via the ACTH stimulation test.
Mechanism of Action
Agonist of melanocortin 2 receptor (MC2R) on adrenal cortex, stimulating cortisol and steroidogenesis.
Routes of Administration
Goals & Uses
- Adrenocortical function testingDiagnosticModerate
- Anti-inflammatory therapyTherapeuticModerate
- Adrenal insufficiency diagnosisEndocrinology / DiagnosticsHigh
- ImmunosuppressionTherapeuticLow
Contraindications
- Cushing's syndromeEndocrine DisorderHigh
- Primary adrenocortical insufficiency (Addison's disease)Endocrine DisorderHigh
- Hypersensitivity to peptideAllergyHigh
- Active infectionsInfectious DiseaseModerate
- Hypersensitivity to ACTH analoguesAllergy/ImmunologyHigh
- Active peptic ulcer diseaseGastrointestinalModerate
Adverse Effects
- HypokalemiaElectrolyteUncommon
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- HypertensionCardiovascularUncommonHigh blood pressure
- Injection site reactionsLocalCommon
- Hypersensitivity/anaphylaxisImmunologicalRare
- Nausea/vomitingGastrointestinalCommon
- FlushingVascularCommonWarmth and redness of the skin
- Transient hyperglycemiaMetabolic/EndocrineCommon
- Fluid retention and edemaMetabolicUncommon
Drug Interactions
- Exogenous glucocorticoidsModerate
- Antidiabetic agentsModerate
- NSAIDsModerateMay increase renal risk in susceptible patients
- Diuretics (potassium-wasting)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Diabetes mellitusMetabolicRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionApprovedApproved: Diagnostic testing of adrenal functionVarious brand names.
- JPApprovedApproved: Diagnostic useMarketed as Alsactide.
- United StatesApprovedApproved: ACTH stimulation testMarketed as Cosyntropin.
- United KingdomUnknownTetracosactide (Synacthen) is the preferred ACTH analogue in the UK; alsactide approval status is unclear.
Approved in several jurisdictions for diagnostic use; marketed under various brand names (e.g., Cosyntropin, Synacthen).
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Alsactide?
Alsactide (tetracosactide, ACTH 1‑24) is a synthetic peptide used diagnostically to assess adrenal function via the ACTH stimulation test.
What is Alsactide used for?
Alsactide is educationally associated with: Adrenocortical function testing, Anti-inflammatory therapy, Adrenal insufficiency diagnosis, Immunosuppression. Educational only — not medical advice.
How is Alsactide administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Alsactide?
Reported adverse effects include: Hypokalemia, Hyperglycemia, Hypertension, Injection site reactions, Hypersensitivity/anaphylaxis, Nausea/vomiting, Flushing, Transient hyperglycemia, Fluid retention and edema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Alsactide?
Recorded contraindications: Cushing's syndrome, Primary adrenocortical insufficiency (Addison's disease), Hypersensitivity to peptide, Active infections, Hypersensitivity to ACTH analogues, Active peptic ulcer disease. Consult a qualified clinician before use.